Would you recommend adjuvant therapy for a non-invasive Grade 3 endometrioid endometrial cancer that is P53 wild-type and MMR deficient (due to methylation)?   


Answer from: at Academic Institution
Comments
at Methodist Stone Oak Hospital
I agree.
Sign in or Register to read more